Monitoring cancer relapse using non-invasive AI technology
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
This study is testing a new AI technology to see if it can help find signs of cancer returning in patients who have been treated for breast cancer, melanoma, or gastrointestinal neuroendocrine tumors before any symptoms show up.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05196087 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze biospecimens from patients with breast cancer, melanoma, and gastrointestinal neuroendocrine tumors who have undergone curative treatment. By utilizing advanced molecular profiling techniques, including liquid biopsies and circulating tumor DNA analysis, the study seeks to detect molecular residual disease (MRD) before it becomes clinically evident. The goal is to develop AI-based models that can identify patients at high risk of relapse, enabling early intervention strategies to improve relapse-free survival rates.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed early-stage or locally advanced solid tumors who have undergone curative treatment.
Not a fit: Patients with advanced cancer who are not undergoing curative treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of cancer relapse and improved survival outcomes for patients.
How similar studies have performed: Other studies utilizing similar molecular profiling and AI approaches have shown promise in early cancer detection and monitoring.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with histological confirmation of a solid tumor. 2. Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment. 3. Patient must be ≥ 18 years old. 4. All patients must have signed and dated an informed consent form. Exclusion Criteria: None
Where this trial is running
Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Lillian Siu, MD — Princess Margaret Hospital, Canada
- Study coordinator: Celeste Yu, MSc
- Email: celeste.yu@uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.